Article
Clinical Neurology
Hee-Jin Kim, YongSoo Shim, Hyun Jeong Han, Byeong C. C. Kim, Kee Hyung Park, So Young Moon, Seong Hye Choi, Dong Won Yang, Bora Yoon, Eun-Joo Kim, Jee Hyang Jeong, Seol-Heui Han
Summary: This study aimed to evaluate the effectiveness of memantine on speech function in patients with moderate to severe Alzheimer's disease who were already on donepezil therapy. The results showed that although the combination therapy was not superior to monotherapy, memantine was still effective in improving behavioral symptoms.
NEUROLOGY AND THERAPY
(2023)
Article
Medicine, Research & Experimental
Mayank Handa, Sachin Nashik Sanap, Rabi Sankar Bhatta, Gajanan Pratap Patil, Rajendra Palkhade, Dhirendra Pratap Singh, Rahul Shukla
Summary: This study aims to develop nanoemulsions for the simultaneous delivery of donepezil and memantine for enhanced brain delivery via the intranasal route. The nanoemulsion was prepared using a low energy emulsification method and characterized using various microscopy techniques. The results demonstrate that the intranasal administration of the nanoemulsion leads to higher brain concentration and better pharmacodynamic effects compared to other routes of administration.
MOLECULAR PHARMACEUTICS
(2023)
Article
Clinical Neurology
Terry E. Goldberg, Seonjoo Lee, Davangere P. Devanand, Lon S. Schneider
Summary: Using per cent slowing of decline as a metric of outcome in Alzheimer's disease clinical trials may be misleading, while Cohen's d is a more valid and informative measure of efficacy. Standardised effect size determines group overlap, influences NNT computations, and provides information on the likelihood of minimum clinically important differences.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Article
Neurosciences
Kazufumi Yoshida, Michael Seo, Yan Luo, Ethan Sahker, Andrea Cipriani, Stefan Leucht, Takeshi Iwatsubo, Orestis Efthimiou, Toshiaki A. Furukawa
Summary: This study developed a personalized prediction model for Alzheimer's disease patients and estimated patient-specific treatment effects of donepezil. Results indicated that donepezil has some efficacy for cognitive function in most patients with AD, but the efficacy may be reduced when combined with antipsychotic drug use.
JOURNAL OF ALZHEIMERS DISEASE
(2022)
Review
Health Care Sciences & Services
Areeba Rashad, Atta Rasool, Muhammad Shaheryar, Azza Sarfraz, Zouina Sarfraz, Karla Robles-Velasco, Ivan Cherrez-Ojeda
Summary: Amyloid-beta (A beta) plaques and aggregated tau are core mechanisms in the development of Alzheimer's disease (AD). This systematic review examines the efficacy and safety of Donanemab, a humanized antibody targeting A beta plaque reduction, in AD patients. The review found that Donanemab led to reduction in A beta plaque levels and a slowing of tau accumulation, resulting in delayed cognitive decline. However, the therapeutic benefits and long-term clinical improvement in AD patients remain unclear, and further trials are needed to explore the potential benefits of Donanemab in modifying the disease's progression.
Letter
Medicine, General & Internal
Dae Hyun Kim, Xihao Li, Shijia Bian, Lee-Jen Wei, Ryan Sun
Summary: This cohort study examines the usefulness of restricted mean survival time as a method for measuring the time to nursing home placement among patients with dementia.
Article
Clinical Neurology
Kee Hyung Park, YoungSoon Yang, Christopher Chen, Yong S. Shim, Jacqueline C. Domingueze, Chan-Nyoung Lee, Kyunghun Kang, Hee-Jin Kim, Seul-Ki Jeong, Jee Hyang Jeong, Zhen Hong, Soo Jin Yoon, Zhen-Xin Zhang, Eun-Joo Kim, Jae-Won Jang, Yansheng Li, Yun Xu, Yu-Te Lin, Qiumin Qu, Chaur-Jong Hu, Chih-Ho Chou, Dongsheng Fan, Nagaendran Kandiah, Yuan-Han Yang, Chi-ieong Lau, Leung-Wing Chu, Huali Wang, San Jung, Seong Hye Choi, SangYun Kim
Summary: This study investigated the treatment discontinuation rates and reasons in Asian patients with Alzheimer's disease newly prescribed donepezil, finding that the primary reason for discontinuation was adverse events, while cognitive function did not significantly worsen over the one-year period.
JOURNAL OF CLINICAL NEUROLOGY
(2021)
Article
Neurosciences
Shigeki Moriguchi, Ryo Inagaki, Takashi Saito, Takaomi C. Saido, Kohji Fukunaga
Summary: Propolis plays a therapeutic role in Alzheimer's disease and other neurodegenerative diseases. In mouse experiments, the combination of propolis and memantine enhances the rescue of cognitive deficits and increases ATP levels through the inhibition of the Kir6.2 channel.
MOLECULAR NEUROBIOLOGY
(2022)
Article
Materials Science, Biomaterials
Mayank Handa, Sachin Nashik Sanap, Rabi Sankar Bhatta, Gajanan Pratap Patil, Suchetana Ghose, Dhirendra Pratap Singh, Rahul Shukla
Summary: This study focuses on the development of mannose-coated PLGA nanoparticles for delivering Donepezil and Memantine. The results show that intranasal administration of the coated nanoparticles leads to higher drug concentration and superior efficacy in neurobehavioral assessments, gene expression analyses, and biochemical estimations.
BIOMATERIALS ADVANCES
(2023)
Review
Clinical Neurology
Scott Carlson, Hyun Kim, Davangere P. Devanand, Terry E. Goldberg
Summary: The article comprehensively examines recent advancements in developing novel cognitive measures that can significantly improve the detection of outcome changes in Alzheimer's disease clinical trials. These new measures aim to detect early cognitive declines by reducing practice effects and exhibiting stronger correlations with Alzheimer's disease biomarkers. The article also discusses efforts in developing remote testing measures protocols and digital phenotyping as solutions to the limitations and inconvenience of in-person testing. However, further validation of the psychometric properties and diagnostic accuracies of these novel measures is required before they can be reliably implemented in Alzheimer's disease clinical trials.
CURRENT OPINION IN NEUROLOGY
(2022)
Article
Psychiatry
Stephen Z. Levine, Yair Goldberg, Kazufumi Yoshida, Myrto Samara, Andrea Cipriani, Takeshi Iwatsubo, Stefan Leucht, Toshiaki A. Furukawa
Summary: This study examined the association between early improvement and subsequent change in cognition in antidementia clinical trials. The results showed that early responders to antidementia medication had more significant improvement in cognition compared to non-early responders, which was supported by sensitivity analysis.
JOURNAL OF PSYCHIATRIC RESEARCH
(2022)
Article
Clinical Neurology
M. ten Kate, F. Barkhof, A. J. J. Schwarz
Summary: This study systematically assessed the consistency and therapeutic class-dependence of treatment effects on clinical outcomes and brain atrophy in clinical trials. The results showed variations in treatment effects across different therapeutic classes, especially in anti-amyloid antibody treatments.
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE
(2023)
Review
Pharmacology & Pharmacy
Debora Nunes, Joana A. Loureiro, Maria Carmo Pereira
Summary: Alzheimer's disease is the most common form of dementia, requiring the development of more effective treatment strategies. Approved drugs for treatment have limited effectiveness and unwanted side effects. Utilizing drug delivery systems can enhance drug efficacy and reduce unwanted side effects.
Article
Clinical Neurology
Roos J. Jutten, Kathryn Papp, Suzanne Hendrix, Noel Ellison, Jessica B. Langbaum, Michael C. Donohue, Jason Hassenstab, Paul Maruff, Dorene M. Rentz, John Harrison, Jeffrey Cummings, Philip Scheltens, Sietske A. M. Sikkes
Summary: Using the right outcome measure is crucial in clinical trials. However, there has been relatively less progress in the evolution of clinical outcome assessments (COAs) for the early stages of Alzheimer's disease (AD). This paper aims to provide guidance for the design and evaluation of COAs for use in early AD trials and proposes a framework for assessing clinically meaningful changes. Recommendations are also given to facilitate the implementation of more effective cognitive outcome measures in AD trials.
ALZHEIMERS & DEMENTIA
(2023)
Article
Multidisciplinary Sciences
Ehsan Yaghmaei, Albert Pierce, Hongxia Lu, Yesha M. Patel, Louis Ehwerhemuepha, Ahmad Rezaie, Seyed Ahmad Sajjadi, Cyril Rakovski
Summary: Alzheimer's disease is a common type of dementia with no cure. Drug therapies like Donepezil and Memantine aim to delay mental decline and improve cognition. A study found that the combined use of Donepezil and Memantine significantly reduces the number of hospital visits per year for AD patients, leading to substantial cost reduction.